Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe gut for HIV's secret hiding spots

NCT ID NCT01038401

Knowledge-focused Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at why HIV remains in the body even when standard treatment keeps virus levels undetectable in the blood. Researchers will take small tissue samples from the gut and blood of 30 HIV-positive adults on effective therapy. The goal is to understand how the virus persists in gut tissue, which may help develop future strategies to eliminate it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal why HIV hides in the gut, pointing toward new strategies to eliminate these viral reservoirs.
What could go wrong
This is a small, observational study with only 30 participants. It does not test a new treatment, so any insights are preliminary and may not lead to direct therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Sep 2008

Finished

May 2010

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HIV-1 infection (ELISA and western-blot tests) * Continuous antiretroviral therapy \>= 12 months * Plasma HIV-1 RNA =\< 40 copies/ml \>= 6 months * Indication of gastro-intestinal endoscopy * Age \>= 18-year old * Physical examination * Informed consent Exclusion Criteria: * Plasma HIV-1 RNA \> 40 copies/ml in the last 6 months * Involvement in a HIV vaccine study * Treatment with interferon-alpha or PEG- interferon-alpha in the last 6 months * Treatment with interleukin-2 in the last 6 months * Decompensated cirrhosis * Abnormal hemostasis tests * Inflammatory bowel disease ; coeliac disease * Lymphoma * Blood transfusion in the last 6 months * Absence of social security (health insurance) * Pregnant or breastfeeding woman * Incapable adult

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infection

Contacts and locations

Locations

  • ANRS center from Toulouse

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.